Gilead Sciences, Inc. (GILD ) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The company’s primary areas of focus are immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus (HCV) and chronic hepatitis B virus (HBV), oncology and inflammation, and serious cardiovascular and respiratory conditions. The company has two high-profile treatments: Harvoni and Sovaldi. These two drugs accounted for nearly 60% of the company’s revenue in both quarters of 2015.
Additionally, Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands approximately 75% of the U.S. treatment market and more than 50% worldwide.
Gilead Sciences recently started paying a quarterly dividend of $0.43 per share. Its first payout was on 6/29/2015. It’s going Ex-Dividend again on 9/14/2015. Its annual payout comes to $1.72, yielding 1.50% on its current price of $114.